# Use of a Novel Artificial Intelligence Assisted Platform to Assess Optimal Dosing and Treatment Strategy of Erythropoiesis-stimulating Agents (ESA) in Hemodialysis Patients

> **NCT05032651** · NA · UNKNOWN · sponsor: **Kaohsiung Medical University Chung-Ho Memorial Hospital** · enrollment: 130 (estimated)

## Conditions studied

- End Stage Renal Disease on Dialysis

## Interventions

- **DEVICE:** novel artificial intelligence assisted platform

## Key facts

- **NCT ID:** NCT05032651
- **Lead sponsor:** Kaohsiung Medical University Chung-Ho Memorial Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-03-19
- **Primary completion:** 2023-12-23
- **Final completion:** 2023-12-23
- **Target enrollment:** 130 (ESTIMATED)
- **Last updated:** 2021-10-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05032651

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05032651, "Use of a Novel Artificial Intelligence Assisted Platform to Assess Optimal Dosing and Treatment Strategy of Erythropoiesis-stimulating Agents (ESA) in Hemodialysis Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05032651. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*